Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Relapsed CAR-T

MM 88 Poseida PBMCS – 101 – 001

Open-Label, Multi-Center, Single Ascending Dose Study to Assess the Safety of P-BMCA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Post Auto

MM 82

Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Must have had transplant due to high-risk features / Engraftment of neutrophils ANC greater than 1000 / Engraftment of platelets, PLT greater than 60 / Achievement of at least a PR prior to transplant / Absence of GI symptoms / Cord blood or haplo transplant not allowed

MM 42 SCRI Millennium

Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD)

Criteria to qualify for study: Drug used in study:
  • Relapsed Refractory

MM 75 CA209602 Bristol-Myers Squibb

An Open-Label Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory MM.

ON HOLD

Criteria to qualify for this study: Drug used in study:
  • R/R, AML/MM/DLBCL

HEMREF 51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247"

Criteria to qualify for this study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.